Exosomes for hair loss: promise, evidence and limits

Exosomes are tiny vesicles released by cells, including stem cells, that carry proteins and genetic material to other cells. In laboratory studies they stimulate the cells that drive hair growth, activate follicle stem cells and support blood vessel formation. In people, the evidence is still early: small studies and case reports, without large controlled trials.

How might exosomes help hair grow?

A 2025 review in Dermatologic Surgery summarised the preclinical findings: exosomes may promote hair growth by stimulating dermal papilla cells, activating hair follicle stem cells and promoting new blood vessels. Mechanisms reported in alopecia studies include activation of the Wnt/β-catenin pathway, which is central to the hair growth cycle, and an anti-inflammatory effect.

What does the clinical evidence show?

The same review found nine clinical studies relevant to hair loss, with 125 patients in total, and side effects were rare. A 2025 systematic review on alopecia areata found 40 eligible studies, but only two of them were clinical; most were laboratory or animal research. Both reviews call for larger, well-designed trials and for consistent manufacturing standards.

Professor Nilforoushzadeh's group has published three case reports using exosomes derived from adipose tissue:

• Refractory alopecia areata: two patients whose disease had resisted multiple treatments improved after a single session, with severity scores falling from 79.6 to 59.6 and from 70.2 to 58.6 at three months, without adverse events.
• Lichen planopilaris: a patient unresponsive to standard treatment showed preliminary signs of better symptom control and hair preservation.
• Hair shaft abnormality: a child who had not responded to minoxidil or PRP showed improved hair structure, strength and growth within three months.

Case reports describe what happened in individual patients. They are a reason to run trials, not proof that a treatment works.

What are the limits?

Exosome products vary widely in their source, concentration and purity, and regulation has not caught up. The review in Dermatologic Surgery notes that in the wider field of dermatology at least ten serious adverse events have been reported. Exosome treatment should be given by a physician, with a product whose source and preparation are known, and alongside treatments with stronger evidence. For an overview of those, see the hair restoration guide.